OBJECTIVES: Video-assisted thoracoscopic surgery (VATS) is possibly associated with reduced acute pain and narcotics consumption when compared to open surgery, but little is known about the long-term effect. The goal of our study was to evaluate whether narcotics consumption is consistently lower after VATS for early stage non-small cell lung cancer (NSCLC), as compared to open surgery, during one-year follow-up.
INTRODUCTION
Video-assisted thoracoscopic surgery (VATS) is a minimally invasive alternative to open thoracotomy in early stage non-small cell lung cancer (NSCLC) [1, 2] . Due to its minimally invasive nature, VATS is associated with reduced acute morbidity, such as pain, and with similar or even better long-term oncological outcome in treating this disease [3, 4] . Whether VATS is associated with reduced post-operative pain is controversial but most of the relevant studies have reported only short-term pain results and little is known about the long-term impact of VATS on pain or narcotics consumption [1, 3, [5] [6] [7] [8] [9] . To our knowledge, when comparing VATS to open surgery, only two studies have reported pain evaluation for at least one year after surgery [10, 11] . Both of these were based on subjective rating. In order to objectively examine our hypothesis that VATS is associated with, not only less acute pain, but also reduction in sustained pain effect, we designed this retrospective cohort study to evaluate whether narcotics consumption is consistently lower, over a one-year follow-up period, after VATS for early stage NSCLC, as compared to following open surgery.
MATERIALS AND METHODS

Data source
of National Health Insurance (NHI) and the Department of Health, giving complete information regarding cancer registry and reimbursement data for the whole Taiwan population . For six major cancer types-including lung cancer-the 'Long Form' cancer registry within CCHIA provides information on individual demographics, tumour histology, location and stage of disease, plus primary surgical, radiation and systematic treatment [13] . NHI is a single-payer, compulsory social insurance program that provides health insurance cover to almost all citizens in Taiwan. Extensive services were covered under the NHI, including outpatient visits, hospitalization, medication, home nursing care, certain screening and preventive services, laboratory tests and diagnostic imaging, dental care et al., without strict referral limitation [14, 15] . All the above data were included in the CCHIA in de-identified form.
Study cases identification and study design
Our study cases were those newly diagnosed with clinical Stage I NSCLC, who received primary lung resection in the year 2007. The detail flow chart of case identification is explained as follows: we identified those newly diagnosed with clinical Stage I NSCLC in the year 2007. We limited our study cases to those who received index surgery (the most advanced surgery, classified as pneumonectomy vs lobectomy vs sublobectomy) within three months following diagnosis, without neoadjuvant treatment. We then identified the reimbursement codes, corresponding to the index admission during which the index surgery was performed. The date of this admission was used as the index date. We further limited our cases to those patients whose surgical types in Cancer Registry's "Long Form" is compatible with the surgical types according to claimed reimbursement codes, so as to ensure data quality. Finally, we determined the main explanatory variable (VATS or open surgery) based on the different reimbursement codes for the index surgery. The codes for thorascopic wedge or partial resection of the lung, thorascopic lobectomy and thorascopic pneumonectomy were used as indicators for VATS, whereas those for wedge or partial resection of the lung, segmental resection, sleeve resection, combined resection of lung cancer, lobectomy, bilobectomy, total pneumonectomy, pneumonectomy with concomitant thoracoplasty or bronchoplasty, were used as indicators for open surgery [16] . These codings were usually correct, given the current fee-for-services reimbursement system in NHI [15] . Details such as surgical approaches were not available in these reimbursement codes. Then we compared the use of narcotics, within the year following the index date, between the VATS and open surgery groups. This study was exempt from Institutional Review Board scrutiny because the CCHIA contains de-identified data and is publicly available through the proper application process [17] .
Narcotics identification
We defined narcotics as either Level 1 or Level 2 drugs, as regulated by the Taiwan Department of Health, to represent the potential severe long-term surgical sequelae [18] . We did not include non-steroid anti-inflammatory drugs because they were usually helpful for mild-to-moderate but not severe pain [19] . The prescribed doses of the narcotic drugs were obtained from the reimbursement records. To report the summary narcotics consumption, we used an equiananalgesic dose chart obtained from the literature [19] [20] [21] to convert narcotics consumption to equivalent doses in mg of intravenous morphine, making the assumption that injected drugs were administered intravenously.
Statistical analyses
Descriptive analysis, chi-square and unpaired t-test were used to compare narcotics consumption between the VATS and open surgery groups. SAS 9.2 software (SAS Institute, Cary, NC, USA) was used for all statistical analyses.
RESULTS
Patient characteristics of the study cases (Table 1) We identified as our study cases 329 newly diagnosed clinical Stage I NSCLC patients who received primary lung resection in 2007. We excluded those who underwent pneumonectomy as there were only two such cases. The characteristics of our study population are described in Table 1 . One hundred and fourteen (34.65%) of our study cases received VATS instead of open surgery. Most of these characteristics were balanced between VATS and open surgery, except that a higher percentage of Narcotics consumption: temporal trend. VATS was associated with lower narcotics consumption during the index admission: mean (± standard deviation) equivalent dose of intravenous morphine was 54.6 ± 77 vs 71.4 ± 240 mg). The trend extended to the period between the second and twelfth months after index date (mean dose 73.8 ± 360 vs 149.5 ± 848 mg) and led to lower annual narcotics consumption (mean 132 ± 377 vs 226 ± 935 mg). The percentage of narcotics users decreased gradually over time (VATS vs open surgery at 1 month, 3 months and 6 months: 20%, 15%, 11% vs 22%, 15%, 9%, respectively). The percentages at 12 months were, similarly, both less than 5% but were not reported in accordance with CCHIA policy. The per quarter temporal trend is shown in Fig. 1 .
DISCUSSION
Our study provided objective evidence that, during one-year follow-up, narcotics consumption is consistently lower after VATS for early stage NSCLC, when compared to open surgery. To our knowledge, this is the first such objective comparison covering a full year after surgery. The impact on pain status after VATS is somewhat less clear in the literature. Due to its minimally invasive nature, VATS is possibly associated with reduced postoperative pain. On the other hand, 'VATS procedures still have the potential to induce unbearable pain due to direct intercostal neurovascular injury resulting from excessive torquing of the trocar and endosurgical instrument access in the intercostal spaces' according to Zhu et al. [1] . Also, as stated in a systematic review by Yan et al. [3] , 'The results of postoperative pain could not be assessed, since most studies did not report this outcome'. By the way, thoracotomy is one of the most painful surgical procedures and post-operative pain can be longlasting. Despite the general belief that VATS might be associated with less postoperative pain, few studies have provided evidence regarding its long-term impact [10, 11] . Our study was based on narcotics consumption instead of subjective rating, so our results should, in theory, be more accurate. They indicated that VATS is not only associated with lower narcotics consumption in the acute stage but that the effect also continues for at least one year. When viewed together with other cost and effectiveness studies, this study suggests that it is likely that VATS is a safe, effective and cost-effective strategy for eligible early stage NSCLC patients [3] .
LIMITATIONS
The major limitation of our study is its retrospective and nonrandomized nature, so we cannot completely exclude bias. The selection of open surgery or VATS was non-randomized and possibly related to the surgeon's preferences or other unobserved bias. However, most of the clinical variables were comparable between the 'VATS' and 'open' groups in our study. There may also be classification bias: for example, based on claims data, we were unable to differentiate intravenous morphine from intrathecal, epidural, nerve block, or intrapleural usage, although the method of administration was unlikely to be other than intravenous following discharge while we observed consistently lower narcotics consumption even after discharge. Based on the reimbursement codes, we were unable to differentiate details such as surgical approach, VATS conversion rate of open surgery, the incision size, and port number of VATS. Due to these limitations, our findings should be interpreted with caution and further prospective, randomized studies or registration with more detail would be helpful to clarify this issue.
CONCLUSIONS
In this retrospective cohort study, narcotics consumption is consistently lower following VATS for early stage non-small cell lung cancer, as compared to following open surgery, over a one-year follow-up period. Prospective studies would be of great value in further evaluation of this finding. 
